Assignee
ZENITH EPIGENETICS LTD
CA·18 granted patents·5 pending applications·105 citations·filing 2013–2024
Top patents by PatentIndex Score
23 records- 0196US9765039B2Biaryl derivatives as bromodomain inhibitorsZENITH EPIGENETICS LTD·Filed 2013·Granted Sep 19, 2017·27 cites·4 claims
- 0294US9861637B2Heterocyclic compounds as bromodomain inhibitorsZENITH EPIGENETICS LTD·Filed 2017·Granted Jan 9, 2018·20 cites·19 claims
- 0394US9662311B2Substituted bicyclic compounds as bromodomain inhibitorsZENITH EPIGENETICS LTD·Filed 2014·Granted May 30, 2017·25 cites·6 claims
- 0489US10363257B2Bicyclic bromodomain inhibitorsZENITH EPIGENETICS LTD·Filed 2018·Granted Jul 30, 2019·8 cites·48 claims
- 0587US9855271B2Quinazolinones as bromodomain inhibitorsZENITH EPIGENETICS LTD·Filed 2014·Granted Jan 2, 2018·12 cites·19 claims
- 0686US10292968B2Substituted heterocycles as bromodomain inhibitorsZENITH EPIGENETICS LTD·Filed 2015·Granted May 21, 2019·6 cites·30 claims
- 0786US10010556B2Bicyclic bromodomain inhibitorsZENITH EPIGENETICS LTD·Filed 2017·Granted Jul 3, 2018·4 cites·54 claims
- 0880US10226451B2Substituted bicyclic compounds as bromodomain inhibitorsZENITH EPIGENETICS LTD·Filed 2017·Granted Mar 12, 2019·2 cites·5 claims
- 0976US10166215B2Substituted bicyclic compounds as bromodomain inhibitorsZENITH EPIGENETICS LTD·Filed 2017·Granted Jan 1, 2019·1 cites·14 claims
- 1072US11446306B2Bicyclic bromodomain inhibitorsZENITH EPIGENETICS LTD·Filed 2020·Granted Sep 20, 2022·0 cites·22 claims
- 1166US10772892B2Bicyclic bromodomain inhibitorsZENITH EPIGENETICS LTD·Filed 2019·Granted Sep 15, 2020·0 cites·15 claims
- 1265US11026926B2Substituted bicyclic compounds as bromodomain inhibitorsZENITH EPIGENETICS LTD·Filed 2019·Granted Jun 8, 2021·0 cites·7 claims
- 1364US12145932B2Method of manufacturing a solid form of a BET bromodomain inhibitorZENITH EPIGENETICS LTD·Filed 2019·Granted Nov 19, 2024·0 cites·21 claims
- 1463US2025034142A1Method of manufacturing a solid form of a bet bromodomain inhibitorZENITH EPIGENETICS LTD·Filed 2024·Application pending·0 cites
- 1552US11607405B2Combination therapy for the treatment of triple-negative breast cancerZENITH EPIGENETICS LTD·Filed 2019·Granted Mar 21, 2023·0 cites·17 claims
- 1649US10500209B2Quinazolinones as bromodomain inhibitorsZENITH EPIGENETICS LTD·Filed 2017·Granted Dec 10, 2019·0 cites·24 claims
- 1746US10710992B2Substituted pyridinones as bromodomain inhibitorsZENITH EPIGENETICS LTD·Filed 2015·Granted Jul 14, 2020·0 cites·4 claims
- 1845US10179125B2Substituted pyridines as bromodomain inhibitorsZENITH EPIGENETICS LTD·Filed 2015·Granted Jan 15, 2019·0 cites·33 claims
- 1944US10231953B2Inhibitors of bromodomainsZENITH EPIGENETICS LTD·Filed 2015·Granted Mar 19, 2019·0 cites·3 claims
- 2041US2022117942A1Combination therapy for the treatment of prostate cancerZENITH EPIGENETICS LTD·Filed 2019·Application pending·0 cites
- 2136US2019263799A11h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitorsZENITH EPIGENETICS LTD·Filed 2016·Application pending·0 cites
- 2235US2019055235A1Substituted bicyclic compounds as bromodomain inhibitorsZENITH EPIGENETICS LTD·Filed 2015·Application pending·0 cites
- 2333US2022047563A1Combination therapy for the treatment of estrogen-receptor positive breast cancerZENITH EPIGENETICS LTD·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ZENITH EPIGENETICS LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →